Kadmon has posted positive and more detailed data out of its so-called ROCKstar pivotal trial of KD025 in chronic graft-versus-host disease (cGVHD).

Transparent Human Organs To Study Organ Functioning

Siegfried Reich has ended his seven-year involvement with Effector Therapeutics. Reich co-founded Effector and served as its senior vice president of research but has moved on to take up the chief scientific officer position at Turning Point Therapeutics.

BIA Separations, a leading bio-chromatography development and manufacturing company, announced it has signed a licensing agreement with the University of Zagreb to commercialize a novel elution method that helps preserve the integrity, infectivity and potency of viruses during immunoaffinity purification. The University of Zagreb will provide BIA Separations with access to proprietary technology, while BIA Separations will market the technology to biopharma, biotech and life science industries globally. As part of the agreement, research teams from both organizations will collaborate to develop follow-on technologies to support the purification of viruses and viral vectors for research and clinical use.

StemBioSys, Inc. (StemBioSys) and CarTox, Inc. (Cartox) are pleased to announce that StemBioSys has acquired a majority stake in Cartox. StemBioSys will acquire all remaining equity of Cartox subject to the achievement of certain milestones.

Last fall, a late-stage brain cancer flop prompted Tocagen to cut 65% of its workforce to stay afloat. Now, out of options, the one-time cancer specialist will become Forte Biosciences’ route to the public markets.

BioMarin’s hemophilia A drug has been set an Aug. 21 PDUFA date as the California biotech looks to gain a speedy approval for the first-ever gene therapy for the bleeding disease.

The former CEO of the molecular testing company Foundation Medicine, Troy Cox, has been named chairman of the Swiss big data firm Sophia Genetics after serving on its board of directors for less than a year.

Everest Medicines has named Eli Lilly veteran Kerry Blanchard as its CEO. Blanchard takes up the top job at the Shanghai-based biopharma company on the back of a career built around a 17-year spell at Lilly.

Genfit’s shares were in the red Friday morning after the French biotech announced it was delaying a data readout for its potential blockbuster fatty liver hopeful elafibranor.